This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Colby Pharmaceutical Company
Drug Names(s): MKC1106-PP
Description: MKC1106-PP is a multi-component active immunotherapy. It is a DNA vector with two synthetic peptides and targets tumour-related antigens PRAME (preferential antigen of melanoma) and PSMA (prostate specific membrane antigen), to induce a cell-mediated immune response.
Partners: MannKind Corporation
Additional information available to subscribers only: